Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

详细信息    查看全文

• 作者：Irene Karam (1) (2)
  Sarah Hamilton (1) (2)
  Alan Nichol (1) (2)
  Ryan Woods (3) (4)
  Caroline Speers (3) (4)
  Hagen Kennecke (1) (5)
  Scott Tyldesley (1) (2)
  
• 关键词：Breast cancer ; Brain metastasis ; Brain irradiation ; Trastuzumab ; HER2 status
• 刊名：Radiation Oncology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：8
• 期：1
• 全文大小：221KB
• 参考文献：1. Leyland-Jones B: Human epidermal growth factor receptor 2鈥損ositive breast cancer and central nervous system metastases. / J Clin Oncol 2009, 27:5278鈥?286. CrossRef
  2. Chia SK, Speers CH, D鈥檡achkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O鈥檙eilly SE, Olivotto IA: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. / Cancer 2007, 110:973鈥?79. CrossRef
  3. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, Supportive Care Guidelines Group of Cancer Care Ontario鈥檚 Program in Evidence-based Care: Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. / Cancer Treat Rev 2005, 31:256鈥?73. CrossRef
  4. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N: Whole brain radiotherapy for the treatment of multiple brain metastases. / Cochrane Database Syst Rev 2012, 4:CD003869.
  5. Spector NL, Blackwell KL: Understanding the mechanisms behind Trastuzumab therapy for human epidermal growth factor receptor 2鈥損ositive breast cancer. / J Clin Oncol 2009, 27:5838鈥?847. CrossRef
  6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. / N Engl J Med 2005, 353:1673鈥?684. CrossRef
  7. Slamon D, Leyland-Jones B, Shak S, / et al.: Addition of herceptin [Superscript TM] (humazined anti-HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. / Proc Am Soc Clin Oncol 1998, 17:98a.
  8. Lin NU, Winer EP: Brain metastases: the HER2 paradigm. / Clin Cancer Res 2007, 13:1648鈥?655. CrossRef
  9. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. / N Engl J Med 1990, 322:494鈥?00. CrossRef
  10. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. / J Clin Oncol 2008, 26:5697鈥?704. CrossRef
  11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. / Int J Radiat Oncol Biol Phys 1997, 37:745鈥?51. CrossRef
  12. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. / Cancer 2006, 107:696鈥?04. CrossRef
  13. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. / Cancer 2003, 97:2972鈥?977. CrossRef
  14. Stemmler H, Heinemann V: Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. / Oncologist 2008, 13:739鈥?50. CrossRef
  15. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW: Survival in patients with brain metastases from breast cancer The importance of HER-2 status. / Cancer 2008, 112:2359鈥?367. CrossRef
  16. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG: Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. / Br J Cancer 2012, 106:25鈥?1. CrossRef
  17. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. / Cancer 1979, 44:1913鈥?918. CrossRef
  18. Boogerd W, Vos VW, Hart AA, Baris G: Brain metastases in breast cancer; natural history, prognostic factors and outcome. / J Neurooncol 1993, 15:165鈥?74. CrossRef
  19. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. / Int J Radiat Oncol Biol Phys 2008, 70:510鈥?14. CrossRef
  20. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. / Int J Radiat Oncol Biol Phys 2010, 77:655鈥?61. CrossRef
  21. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M: Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. / J Clin Oncol 2012, 30:419鈥?25. CrossRef
  
• 作者单位：Irene Karam (1) (2)
  Sarah Hamilton (1) (2)
  Alan Nichol (1) (2)
  Ryan Woods (3) (4)
  Caroline Speers (3) (4)
  Hagen Kennecke (1) (5)
  Scott Tyldesley (1) (2)
  
  1. University of British Columbia, Vancouver, BC, Canada
  2. Radiation Therapy Program, BC Cancer Agency 鈥?Vancouver Centre, 600 west 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
  3. Cancer Surveillance and Outcomes, Population Oncology, BC Cancer Agency, Vancouver, BC, Canada
  4. Breast Cancer Outcomes Unit, BC Cancer Agency, Vancouver, BC, Canada
  5. Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada
  

文摘

Purpose To evaluate the survival of patients with human epidermal growth factor receptor 2 (HER2) positive and negative metastatic breast cancer irradiated for brain metastases before and after the availability of trastuzumab (T). Materials and methods Women diagnosed with brain metastasis from breast cancer in two eras between 2000 and 2007 (T-era, n = 441) and 1986 to 1992 (PreT-era, n = 307), treated with whole brain radiotherapy (RT) were identified. In the T-era, HER2 testing was part of routine clinical practice, and in the preT-era 128/307 (42%) cases had HER2 testing performed retrospectively on tissue microarrays. Overall survival (OS) was estimated using the Kaplan-Meier method and comparisons between eras used log-rank tests. Results In the preT- and T-era cohorts, the rate of HER2 positivity was 40% (176/441) and 26% (33/128) (p < 0.001). The median time from diagnosis to brain RT was longer in the preT-era (3.3 years versus 2.3 years, p < 0.001). Survival after brain RT was improved in the T-era compared to the preT-era (1-year OS 26% versus 12%, p < 0.001). The 1-year OS rate for HER2 negative patients was 20% in both eras (p = 0.97). Among HER2 positive patients, the 1-year OS in the preT-era was 5% compared to 40% in the T-era (p < 0.001). Conclusions Distinct from patients with HER2 negative disease in whom no difference in survival after brain RT was observed over time, patients with HER2 positive brain metastases experienced significantly improved survival subsequent to the availability of trastuzumab.